{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T14:35:34Z","timestamp":1774967734345,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00066-021-01835-9","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T20:59:34Z","timestamp":1630702774000},"page":"1131-1142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Preclinical evaluation of PEGylated liposomal doxorubicin as an effective radiosensitizer in chemoradiotherapy for lung cancer"],"prefix":"10.1007","volume":"197","author":[{"given":"Jenny Ling-Yu","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Kai","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6287-3646","authenticated-orcid":false,"given":"Yu-Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Yi","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Sen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Chi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Ming","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Hsin","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Jium","family":"Shieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"key":"1835_CR1","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1056\/NEJMra1608986","volume":"377","author":"DE Citrin","year":"2017","unstructured":"Citrin\u00a0DE (2017) Recent developments in radiotherapy. N\u00a0Engl J Med 377:1065\u20131075. https:\/\/doi.org\/10.1056\/NEJMra1608986","journal-title":"N Engl J Med"},{"key":"1835_CR2","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.ijrobp.2009.12.070","volume":"79","author":"S Tyldesley","year":"2011","unstructured":"Tyldesley\u00a0S, Delaney\u00a0G, Foroudi\u00a0F, Barbera\u00a0L, Kerba\u00a0M, Mackillop\u00a0W (2011) Estimating the need for radiotherapy for patients with prostate, breast, and lung cancers: verification of model estimates of need with radiotherapy utilization data from British Columbia. Int J Radiat Oncol Biol Phys 79:1507\u20131515. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.12.070","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1835_CR3","doi-asserted-by":"publisher","first-page":"1600424","DOI":"10.1002\/ppsc.201600424","volume":"34","author":"JL Chen","year":"2017","unstructured":"Chen JL, Tsai YC, Tsai MH et al (2017) Prominin-1-specific binding peptide-modified apoferritin nanoparticle carrying irinotecan as a novel radiosensitizer for colorectal cancer stem-like cells. Part Part Syst Charact 34:1600424. https:\/\/doi.org\/10.1002\/ppsc.201600424","journal-title":"Part Part Syst Charact"},{"key":"1835_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00066-018-1418-8","volume":"195","author":"YS Huang","year":"2019","unstructured":"Huang\u00a0YS, Chen\u00a0JL, Chen\u00a0JY et al (2019) Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography. Strahlenther Onkol 195:707\u2013718. https:\/\/doi.org\/10.1007\/s00066-018-1418-8","journal-title":"Strahlenther Onkol"},{"key":"1835_CR5","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.ijrobp.2015.11.030","volume":"94","author":"A Warner","year":"2016","unstructured":"Warner\u00a0A, Dahele\u00a0M, Hu\u00a0B et al (2016) Factors associated with early mortality in patients treated with concurrent chemoradiation therapy for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 94:612\u2013620. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.11.030","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1835_CR6","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/jnci\/djm027","volume":"99","author":"N Tang","year":"2007","unstructured":"Tang\u00a0N, Du\u00a0G, Wang\u00a0N, Liu\u00a0C, Hang\u00a0H, Liang\u00a0W (2007) Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J\u00a0Natl Cancer Inst 99:1004\u20131015. https:\/\/doi.org\/10.1093\/jnci\/djm027","journal-title":"J Natl Cancer Inst"},{"key":"1835_CR7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.radonc.2017.08.037","volume":"125","author":"JP Nesseler","year":"2017","unstructured":"Nesseler\u00a0JP, Salleron\u00a0J, Rios\u00a0M et\u00a0al (2017) A retrospective cohort study to assess adjuvant concurrent chemoradiation (CCRT) compared to adjuvant radiation therapy (RT) in the treatment of grade 2 and 3 extremity soft tissue sarcomas. Radiother Oncol 125:160\u2013167. https:\/\/doi.org\/10.1016\/j.radonc.2017.08.037","journal-title":"Radiother Oncol"},{"key":"1835_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.radonc.2017.03.012","volume":"123","author":"JC Rehammar","year":"2017","unstructured":"Rehammar\u00a0JC, Jensen\u00a0MB, McGale\u00a0P et\u00a0al (2017) Risk of heart disease in relation to radiotherapy and chemotherapy with anthracyclines among 19,464 breast cancer patients in Denmark, 1977\u20132005. Radiother Oncol 123:299\u2013305. https:\/\/doi.org\/10.1016\/j.radonc.2017.03.012","journal-title":"Radiother Oncol"},{"key":"1835_CR9","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jconrel.2006.12.002","volume":"118","author":"J Cui","year":"2007","unstructured":"Cui\u00a0J, Li\u00a0C, Guo\u00a0W et\u00a0al (2007) Direct comparison of two pegylated liposomal doxorubicin formulations: Is AUC predictive for toxicity and efficacy? J\u00a0Control Release 118:204\u2013215. https:\/\/doi.org\/10.1016\/j.jconrel.2006.12.002","journal-title":"J Control Release"},{"key":"1835_CR10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1081\/cnv-100103136","volume":"19","author":"AA Gabizon","year":"2001","unstructured":"Gabizon\u00a0AA (2001) Pegylated liposomal doxorubicin: metamorphosis of an old drug into a\u00a0new form of chemotherapy. Cancer Invest 19:424\u2013436. https:\/\/doi.org\/10.1081\/cnv-100103136","journal-title":"Cancer Invest"},{"key":"1835_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.4155\/bio.10.204","volume":"3","author":"W Jiang","year":"2011","unstructured":"Jiang\u00a0W, Lionberger\u00a0R, Yu\u00a0LX (2011) In vitro and in vivo characterizations of PEGylated liposomal doxorubicin. Bioanalysis 3:333\u2013344. https:\/\/doi.org\/10.4155\/bio.10.204","journal-title":"Bioanalysis"},{"key":"1835_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jconrel.2019.06.007","volume":"306","author":"Y Bavli","year":"2019","unstructured":"Bavli\u00a0Y, Winkler\u00a0I, Chen\u00a0BM et al (2019) Doxebo (doxorubicin-free doxil-like liposomes) is safe to use as a\u00a0pre-treatment to prevent infusion reactions to PEGylated nanodrugs. J\u00a0Control Release 306:138\u2013148. https:\/\/doi.org\/10.1016\/j.jconrel.2019.06.007","journal-title":"J Control Release"},{"key":"1835_CR13","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jconrel.2011.03.017","volume":"152","author":"MJ Shieh","year":"2011","unstructured":"Shieh\u00a0MJ, Hsu\u00a0CY, Huang\u00a0LY, Chen\u00a0HY, Huang\u00a0FH, Lai\u00a0PS (2011) Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7\/ADR cells. J\u00a0Control Release 152:418\u2013425. https:\/\/doi.org\/10.1016\/j.jconrel.2011.03.017","journal-title":"J Control Release"},{"key":"1835_CR14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ygyno.2005.10.027","volume":"101","author":"HH Chou","year":"2006","unstructured":"Chou\u00a0HH, Wang\u00a0KL, Chen\u00a0CA et al (2006) Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a\u00a0Taiwanese gynecologic oncology group study with long-term follow-up. Gynecol Oncol 101:423\u2013428. https:\/\/doi.org\/10.1016\/j.ygyno.2005.10.027","journal-title":"Gynecol Oncol"},{"key":"1835_CR15","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.1016\/j.ijrobp.2008.06.751","volume":"72","author":"DW Kim","year":"2008","unstructured":"Kim\u00a0DW, Blackwell\u00a0K, Vujaskovic\u00a0Z et\u00a0al (2008) A Phase I\/II study of neoadjuvant liposomal doxorubicin, paclitaxel and hyperthermia in locally advanced breast cancer. Int J Radiat Oncol Biol Phys 72:S183\u2013S184. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.06.751","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1835_CR16","doi-asserted-by":"publisher","first-page":"S254","DOI":"10.1016\/j.ijrobp.2010.07.608","volume":"78","author":"BM O\u2019Connor","year":"2010","unstructured":"O\u2019Connor\u00a0BM, Lewis\u00a0SA, Borys\u00a0N (2010) Initial results of a\u00a0phase I\/II study evaluating the maximum tolerated dose, pharmacokinetics, safety, and efficacy of hyperthermia and lyso-thermosensitive liposomal (LTSL) doxorubicin in patients with breast cancer recurrence at the chest wall (RCW). Int J Radiat Oncol Biol Phys 78:S254\u2013S245. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.07.608","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1835_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1748-717X-6-135","volume":"6","author":"E Hagtvet","year":"2011","unstructured":"Hagtvet\u00a0E, Roe\u00a0K, Olsen\u00a0DR (2011) Liposomal doxorubicin improves radiotherapy response in hypoxic prostate cancer xenografts. Radiat Oncol 6:135. https:\/\/doi.org\/10.1186\/1748-717X-6-135","journal-title":"Radiat Oncol"},{"key":"1835_CR18","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1200\/JCO.1999.17.11.3512","volume":"17","author":"MI Koukourakis","year":"1999","unstructured":"Koukourakis\u00a0MI, Koukouraki\u00a0S, Giatromanolaki\u00a0A et al (1999) Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J\u00a0Clin Oncol 17:3512\u20133521. https:\/\/doi.org\/10.1200\/JCO.1999.17.11.3512","journal-title":"J Clin Oncol"},{"key":"1835_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/028418600430789","volume":"3","author":"MI Koukourakis","year":"2000","unstructured":"Koukourakis\u00a0MI, Koukouraki\u00a0S, Giatromanolaki\u00a0A et\u00a0al (2000) High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas\u2014rationale for combination with radiotherapy. Acta Oncol 3:207\u2013211. https:\/\/doi.org\/10.1080\/028418600430789","journal-title":"Acta Oncol"},{"key":"1835_CR20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00262-020-02690-w","volume":"70","author":"JL Chen","year":"2021","unstructured":"Chen\u00a0JL, Pan\u00a0CK, Huang\u00a0YS et al (2021) Evaluation of antitumor immunity by a\u00a0combination treatment of high-dose irradiation, anti-PDL1, and anti-angiogenic therapy in murine lung tumors. Cancer Immunol Immunother 70:391\u2013404. https:\/\/doi.org\/10.1007\/s00262-020-02690-w","journal-title":"Cancer Immunol Immunother"},{"key":"1835_CR21","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s00066-016-0951-6","volume":"192","author":"JL Chen","year":"2016","unstructured":"Chen\u00a0JL, Chen\u00a0JP, Huang\u00a0YS et al (2016) Radiosensitization in esophageal squamous cell carcinoma: effect of polo-like kinase 1 inhibition. Strahlenther Onkol 192:260\u2013268. https:\/\/doi.org\/10.1007\/s00066-016-0951-6","journal-title":"Strahlenther Onkol"},{"key":"1835_CR22","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/cvr\/cvz192","volume":"116","author":"M Gy\u00f6ngy\u00f6si","year":"2020","unstructured":"Gy\u00f6ngy\u00f6si\u00a0M, Lukovic\u00a0D, Zlabinger\u00a0K et al (2020) Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance. Cardiovasc Res 116:970\u2013982. https:\/\/doi.org\/10.1093\/cvr\/cvz192","journal-title":"Cardiovasc Res"},{"key":"1835_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1148\/radiol.09091196","volume":"255","author":"SA Solazzo","year":"2010","unstructured":"Solazzo\u00a0SA, Ahmed\u00a0M, Schor-Bardach\u00a0R et al (2010) Liposomal doxorubicin increases radiofrequency ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways. Radiology 255:62\u201374. https:\/\/doi.org\/10.1148\/radiol.09091196","journal-title":"Radiology"},{"key":"1835_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jconrel.2017.08.030","volume":"264","author":"M Alibolandi","year":"2017","unstructured":"Alibolandi\u00a0M, Abnous\u00a0K, Mohammadi\u00a0M et al (2017) Extensive preclinical investigation of polymersomal formulation of doxorubicin versus doxil-mimic formulation. J\u00a0Control Release 264:228\u2013236. https:\/\/doi.org\/10.1016\/j.jconrel.2017.08.030","journal-title":"J Control Release"},{"key":"1835_CR25","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1038\/sj.bjc.6601427","volume":"89","author":"AL Dunne","year":"2003","unstructured":"Dunne\u00a0AL, Price\u00a0ME, Mothersill\u00a0C, McKeown\u00a0SR, Robson\u00a0T, Hirst\u00a0DG (2003) Relationship between clonogenic radiosensitivity, radiation-induced apoptosis and DNA damage\/repair in human colon cancer cells. Br J Cancer 89:2277\u20132283. https:\/\/doi.org\/10.1038\/sj.bjc.6601427","journal-title":"Br J Cancer"},{"key":"1835_CR26","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s13277-010-0042-8","volume":"31","author":"D Eriksson","year":"2010","unstructured":"Eriksson\u00a0D, Stigbrand\u00a0T (2010) Radiation-induced cell death mechanisms. Tumor Biol 31:363\u2013372. https:\/\/doi.org\/10.1007\/s13277-010-0042-8","journal-title":"Tumor Biol"},{"key":"1835_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bcp.2013.06.020","volume":"87","author":"BA Ruggeri","year":"2014","unstructured":"Ruggeri\u00a0BA, Camp\u00a0F, Miknyoczki\u00a0S (2014) Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. Biochem Pharmacol 87:150\u2013161. https:\/\/doi.org\/10.1016\/j.bcp.2013.06.020","journal-title":"Biochem Pharmacol"},{"key":"1835_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5487\/TR.2014.30.1.001","volume":"30","author":"J Jung","year":"2014","unstructured":"Jung\u00a0J (2014) Human tumor xenograft models for preclinical assessment of anticancer drug development. Toxicol Res 30:1\u20135. https:\/\/doi.org\/10.5487\/TR.2014.30.1.001","journal-title":"Toxicol Res"},{"key":"1835_CR29","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2353\/ajpath.2007.060929","volume":"170","author":"JE Talmadge","year":"2007","unstructured":"Talmadge\u00a0JE, Singh\u00a0RK, Fidler\u00a0IJ, Raz\u00a0A (2007) Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 170:793\u2013804. https:\/\/doi.org\/10.2353\/ajpath.2007.060929","journal-title":"Am J Pathol"},{"key":"1835_CR30","doi-asserted-by":"publisher","first-page":"11117","DOI":"10.1038\/s41598-019-47308-z","volume":"9","author":"W Zhang","year":"2019","unstructured":"Zhang\u00a0W, Fan\u00a0W, Rachagani\u00a0S et al (2019) Comparative study of subcutaneous and orthotopic mouse models of prostate cancer: vascular perfusion, vasculature density, hypoxic burden and BB2r-targeting efficacy. Sci Rep 9:11117. https:\/\/doi.org\/10.1038\/s41598-019-47308-z","journal-title":"Sci Rep"},{"key":"1835_CR31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fcell.2020.00041","volume":"8","author":"J Sia","year":"2020","unstructured":"Sia\u00a0J, Szmyd\u00a0R, Hau\u00a0E (2020) Molecular mechanisms of radiation-induced cancer cell death: a\u00a0primer. Front Cell Dev Biol 8:41. https:\/\/doi.org\/10.3389\/fcell.2020.00041","journal-title":"Front Cell Dev Biol"},{"key":"1835_CR32","doi-asserted-by":"publisher","first-page":"e82331","DOI":"10.1371\/journal.pone.0082331","volume":"9","author":"PJ Gaillard","year":"2014","unstructured":"Gaillard\u00a0PJ, Appeldoorn\u00a0CC, Dorland\u00a0R et al (2014) Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PLoS One 9:e82331. https:\/\/doi.org\/10.1371\/journal.pone.0082331","journal-title":"PLoS One"},{"key":"1835_CR33","doi-asserted-by":"publisher","first-page":"e61359","DOI":"10.1371\/journal.pone.0061359","volume":"8","author":"CK Anders","year":"2013","unstructured":"Anders\u00a0CK, Adamo\u00a0B, Karginova\u00a0O et\u00a0al (2013) Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer. PLoS One 8:e61359. https:\/\/doi.org\/10.1371\/journal.pone.0061359","journal-title":"PLoS One"},{"key":"1835_CR34","first-page":"1349","volume":"28","author":"PG Tsoutsou","year":"2008","unstructured":"Tsoutsou\u00a0PG, Froudarakis\u00a0ME, Bouros\u00a0D, Koukourakis\u00a0MI (2008) Hypofractionated\/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC). Anticancer Res 28:1349\u20131354","journal-title":"Anticancer Res"},{"key":"1835_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/s0168-3659(03)00240-2","volume":"91","author":"RM Schiffelers","year":"2003","unstructured":"Schiffelers\u00a0RM, Koning\u00a0GA, ten Hagen\u00a0TL et al (2003) Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J\u00a0Control Release 91:115\u2013122. https:\/\/doi.org\/10.1016\/s0168-3659(03)00240-2","journal-title":"J Control Release"},{"key":"1835_CR36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.canlet.2013.02.020","volume":"335","author":"S Biswas","year":"2013","unstructured":"Biswas\u00a0S, Deshpande\u00a0PP, Perche\u00a0F, Dodwadkar\u00a0NS, Sane\u00a0SD, Torchilin\u00a0VP (2013) Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer. Cancer Lett 335:191\u2013200. https:\/\/doi.org\/10.1016\/j.canlet.2013.02.020","journal-title":"Cancer Lett"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-021-01835-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-021-01835-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-021-01835-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T11:03:37Z","timestamp":1637319817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-021-01835-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,2]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1835"],"URL":"https:\/\/doi.org\/10.1007\/s00066-021-01835-9","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,2]]},"assertion":[{"value":"27 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.L.-Y.\u00a0Chen, C.-K.\u00a0Pan, Y.-L.\u00a0Lin, C.-Y.\u00a0Tsai, Y.-S.\u00a0Huang, W.-C.\u00a0Yang, F.-M.\u00a0Hsu, S.-H.\u00a0Kuo and M.-J.\u00a0Shieh declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All in vivo experimental protocols were approved by the Institutional Animal Care and Use Committee (IACUC 20180464). Humane endpoints were determined according to a clinical scoring system based on that outlined by the IACUC of our institution.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}